Literature DB >> 10491443

RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

.   

Abstract

Entities:  

Year:  1999        PMID： 10491443     DOI： 10.1093/jnci/91.18.1588

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  23 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation.

Authors:  Lin Zhu; Jing Zhang; Hongtao Song; Qinghua Wang; Jianming Tan; Weizhen Wu; Meiqin Lin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 3.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

4.  Prediction of systemic exposure to cyclosporine in Japanese pediatric patients.

Authors:  Toshiyuki Sakaeda; Kazumoto Iijima; Kandai Nozu; Tsutomu Nakamura; Yuka Moriya; Mika Nishikawa; Atsushi Wada; Noboru Okamura; Masafumi Matsuo; Katsuhiko Okumura
Journal:  J Hum Genet       Date:  2006-09-14       Impact factor: 3.172

Review 5.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

6.  Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.

Authors:  H Irene Su; Mary D Sammel; Luke Velders; Michelle Horn; Corrie Stankiewicz; Jennifer Matro; Clarisa R Gracia; Jamie Green; Angela DeMichele
Journal:  Fertil Steril       Date:  2009-04-18       Impact factor: 7.329

Review 7.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

8.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

Review 9.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.

Authors:  Navin Pinto; Susan M Ludeman; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

Review 10.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.